Gene Sequencing

The articles on sequencing the human genome (THE SCIENTIST, October 20, pp. 11-12) were noteworthy not so much for the arguments they put forward in support of the project as for their failure to realistically assess the cost, need and impact of such a project. Certainly, one can scan DNA sequences with computers and determine open reading frames, enhancer sequences, RNA polymerase binding sites, etc. However, without supporting data, these determinations are purely hypothetical. The magnitude o

Written bySidney Kushner
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The articles on sequencing the human genome (THE SCIENTIST, October 20, pp. 11-12) were noteworthy not so much for the arguments they put forward in support of the project as for their failure to realistically assess the cost, need and impact of such a project. Certainly, one can scan DNA sequences with computers and determine open reading frames, enhancer sequences, RNA polymerase binding sites, etc. However, without supporting data, these determinations are purely hypothetical.

The magnitude of the project also needs to be put into perspective. While genomes the size of bacteriophage lambda (49,133 bp) have been determined with considerable effort, the sequence of the entire Escherichia coli chromosome (4 million bp) is still not available, let alone a complete physical map. Gilbert underestimates the problems and time it will take to generate the library of cosmids containing unique 40,000 base-pair inserts. DNA fragments of this size are at the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies